Share This Page
sodium bicarbonate - Profile
✉ Email this page to a colleague
What are the generic sources for sodium bicarbonate and what is the scope of freedom to operate?
Sodium bicarbonate
is the generic ingredient in three branded drugs marketed by Amneal, Anthea Pharma, Aspiro, Exela Pharma, Fresenius Kabi Usa, Hospira, Intl Medication Sys, Long Grove Pharms, Omnivium Pharms, Steriscience, Abbott, and Mallinckrodt Inc, and is included in seventeen NDAs. Additional information is available in the individual branded drug profile pages.Summary for sodium bicarbonate
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 12 |
| NDAs: | 17 |
US Patents and Regulatory Information for sodium bicarbonate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal | SODIUM BICARBONATE | sodium bicarbonate | SOLUTION;INTRAVENOUS | 217523-001 | Jan 13, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Anthea Pharma | SODIUM BICARBONATE | sodium bicarbonate | SOLUTION;INTRAVENOUS | 219701-001 | Jun 26, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Aspiro | SODIUM BICARBONATE | sodium bicarbonate | SOLUTION;INTRAVENOUS | 220788-001 | Apr 15, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Aspiro | SODIUM BICARBONATE | sodium bicarbonate | SOLUTION;INTRAVENOUS | 220788-002 | Apr 15, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Aspiro | SODIUM BICARBONATE | sodium bicarbonate | SOLUTION;INTRAVENOUS | 220788-003 | Apr 15, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Sodium Bicarbonate Drug Investment Scenario and Patent/Regulatory Fundamentals Analysis
Sodium bicarbonate is a widely available, off-patent, multi-indication generic commodity active ingredient with minimal innovation-led IP and no meaningful exclusivity runway. The investment case is dominated by manufacturing economics, regulatory posture (compendial vs FDA-labeled), distribution and contracting strength, and liability risk management, not by patent duration.
Core investment takeaway: treat sodium bicarbonate as a value-chain execution bet (cost, compliance, supply continuity, and customer contracts), not as a platform IP bet.
Sodium bicarbonate is it patented? What IP protects sodium bicarbonate in the US and EU
Answer: Sodium bicarbonate (CAS 144-55-8) is a foundational inorganic salt and is effectively off-patent for most uses and compositions in major markets. IP, where present, tends to be narrow around specific formulations, container-closure systems, manufacturing processes, or labeled combinations rather than the active ingredient itself.
What types of patents can still exist
Even when the active substance is not protected, patents may appear in these buckets:
- Process patents for manufacturing sodium bicarbonate or high-purity grades (crystallization, purification, drying parameters).
- Formulation patents for specific dosage forms (for example, effervescent delivery systems) or stability improvements.
- Device/combination patents for fixed-dose co-products where sodium bicarbonate is one component (less common because the active is generic and combinations are usually also generic).
- Packaging/containment claims tied to gas evolution handling, shelf-life extension, or container-closure compatibility.
How to interpret an IP posture for investing
- If Orange Book listings exist for a sodium bicarbonate-labeled NDA/ANDA product, they often cover narrow aspects tied to that specific product.
- The broader active ingredient market is still dominated by compendial sourcing and generic competition.
- Any remaining patents typically do not create large, durable pricing power because multiple manufacturers can qualify through established supply chains and standard regulatory pathways.
What is the Orange Book status of sodium bicarbonate products
Answer: Sodium bicarbonate products are commonly regulated as approved drug products (NDA/ANDA) and often appear in FDA systems as generic listings or listed compendial products depending on the exact dosage form and labeling. The practical effect for investors is that exclusivity is usually limited and launches face rapid generic competition.
Why “Orange Book status” is often low-leverage for this asset
- The active ingredient is longstanding and broadly manufactured.
- Pricing is driven by commodity dynamics, not by patent-protected demand capture.
- Even if one specific product has an Orange Book patent, competitors can still compete via:
- alternative strengths/dosage forms,
- different label indications,
- and/or direct manufacturing availability through multiple ANDAs.
What matters more than Orange Book listings
- Market share by dosage form and contract status
- Chemistry, manufacturing, and controls (CMC) readiness
- FDA inspection outcomes and batch release performance
- Supply assurance contracts with major wholesalers and institutions
When does sodium bicarbonate lose exclusivity? How long is exclusivity for sodium bicarbonate
Answer: Exclusivity in sodium bicarbonate is typically short or nonexistent for the active ingredient. For most products, the limiting factor is patent life for the specific product if any exist, not regulatory exclusivity.
Practical exclusivity timeline
- Commodity active ingredient: essentially no exclusivity barrier.
- Product-specific exclusivity: if tied to a specific NDA/ANDA formulation or labeling, it typically expires quickly given the age of the market.
- Market structure effect: even where a product remains “protected” on paper, competition can enter through adjacent dosage forms and equivalent therapeutic utility.
What generic entry risks exist for sodium bicarbonate? Paragraph IV and ANDA strategy
Answer: Paragraph IV risk is generally low because the active ingredient is not commonly protected by strong, long-lived patents. New entrants often compete through standard ANDA pathways or via product line extensions rather than aggressive patent challenges.
Entry risk drivers
- Regulatory filing path: established comparability for common strengths and dosage forms lowers barriers.
- CMC scale economics: incumbents and large generics can undercut due to manufacturing throughput advantages.
- Supply continuity: buyers reward uninterrupted supply, making stable large-scale manufacturers advantaged.
Litigation probability
- Lower than for branded specialty drugs because disputes do not block a large protected territory.
- When litigation happens, it often targets narrow product attributes rather than the core API.
How strong is the patent estate for sodium bicarbonate: what patents and who owns them
Answer: For sodium bicarbonate as an active ingredient, the patent estate is weak for long-horizon investment. Any protective IP is usually:
- product-specific,
- narrow in scope,
- or process/quality related.
Who typically holds any remaining relevant IP
- Large generics and specialty pharmaceutical manufacturers sometimes hold patents on:
- specific dosage forms,
- manufacturing improvements,
- or stability and delivery improvements.
- Inorganic salt markets also have utility and process claims in supplier networks, but these do not generally translate into durable pricing power.
What formulations are protected by sodium bicarbonate patents
Answer: The most plausible remaining protections, if any, are around dosage form and stability.
Formulation areas that can attract product-level IP
- Effervescent delivery (if the product exists as an effervescent tablet/sachet type)
- Granulations and dissolution behavior
- Stability in specific container types and humidity control
- Sodium bicarbonate with buffers or co-ingredients for a specific labeled use
- Injection-grade readiness (sterility and container-closure standards)
Investor lens
Even where formulation patents exist, contract purchasing and multi-sourcing usually cap price retention.
What method-of-use patents cover sodium bicarbonate
Answer: Method-of-use patent coverage is unlikely to be meaningful for sodium bicarbonate broadly because the clinical uses are long established (for example, metabolic acidosis support and alkalinization use-cases in specific clinical scenarios). Any remaining method claims are typically narrow.
How to treat method-of-use as an investment factor
- The market is driven by clinical standard-of-care and sourcing availability.
- If a use is standard and widely stocked, payer and provider switching does not hinge on patent protection.
What patent litigation affects sodium bicarbonate
Answer: There is no broad, systemic pattern of high-impact sodium bicarbonate patent litigation that would define a sector-wide risk profile. Litigation, where it occurs, is usually local and tied to a specific dosage form or a specific manufacturer’s labeling/product changes.
What to monitor
- Any disputes tied to specific FDA-approved products (not the API)
- Any injunction risks tied to a specific strength, route, or container-closure configuration
What is the FDA regulatory status of sodium bicarbonate products
Answer: Sodium bicarbonate is regulated as a drug product for labeled indications depending on dosage form and route. Regulatory status typically spans:
- NDA products (original branded or specific manufacturer approvals)
- ANDAs (generic approvals)
- Compendial availability where applicable
Regulatory risk profile
- CMC compliance is the main risk: impurity profiles, stability, and consistent potency.
- Sterility and sterility assurance apply to injectable products.
- Stability in liquid vs solid dosage forms affects shelf-life and logistics.
What commercial factors drive sodium bicarbonate margins
Answer: Margins track raw material cost, manufacturing yields, batch utilization, and logistics. Pricing is constrained by substitutability and high buyer switching ability.
Key margin levers
- Scale manufacturing: lower per-unit conversion and purification cost
- Quality specifications: meeting tighter impurity and assay specs increases acceptance and reduces batch rejects
- Packaging: container-closure compatibility for shelf-life drives cost and returns
- Supply agreements: institutional buyers favor qualified multi-source suppliers but reward reliable lead times
Typical demand characteristics
- Demand is tied to hospital utilization and institutional formularies.
- In stable periods, sodium bicarbonate behaves like a procurement commodity.
- Surge events can raise utilization, but substitution remains easy.
How does sodium bicarbonate compare with other buffering agents as an investment
Answer: Sodium bicarbonate’s differentiator is ubiquity and low differentiation. Investment upside is more dependent on manufacturing scale and execution than product differentiation.
Comparison set
- Sodium citrate / citrate-based buffers: may compete in overlapping settings but do not eliminate bicarbonate demand where bicarbonate is standard.
- Lactated Ringer’s and balanced crystalloids: compete as alternative resuscitation fluids rather than direct “bicarbonate-only” substitutes.
- Carbagenic alkalinization alternatives: usage patterns vary by clinician preference and protocol.
Investment interpretation
- Competitors with differentiated dosage forms can reduce pricing for specific segments.
- Sodium bicarbonate remains a base-stock and hospital formulary staple, supporting volume stability but limiting pricing power.
Geographic coverage: where sodium bicarbonate investment risk differs
Answer: The largest risk differences are in regulatory inspection strictness, compendial acceptance culture, and tendering practices.
US vs EU risk
- US: inspections, batch release controls, and facility compliance dominate.
- EU: tendering and pharmacovigilance systems plus national procurement constraints can shift volume flows quickly.
China/India sourcing dynamics
- Cost competitiveness can support supply but raises quality and compliance risk. High-quality imports can still be competitive if qualification hurdles are met.
What manufacturing and IP barriers block new sodium bicarbonate entrants
Answer: IP barriers are low. Operational barriers are higher.
Manufacturing barriers
- High-purity grade qualification for injectable or tight-spec dosage forms
- Validation of consistent particle size/dissolution for certain solids
- Stability validation and packaging qualification
- Regulatory inspection outcomes
Why this matters for investors
- Investors get more leverage by targeting compliant, scalable plants than by betting on patent timelines.
Revenue exposure: what drives sodium bicarbonate product line growth
Answer: Growth comes from:
- share gains through hospital group tenders,
- expansion of qualified supply,
- new dosage form rollouts by the same manufacturer,
- and replacement of less reliable suppliers.
Risk
- Price compression through multi-sourcing
- Contract re-tendering
- Regulatory observation-driven stoppages
Key Takeaways
- Sodium bicarbonate is a commodity drug active ingredient with limited durable patent leverage.
- Exclusivity and Paragraph IV dynamics are typically low-salience; product-specific protections, if any, are narrow.
- Investment fundamentals are governed by manufacturing scale, CMC reliability, inspection readiness, packaging and stability performance, and contracting/distribution reach.
- Risk is primarily execution and regulatory compliance rather than patent litigation or generic exclusivity cliffs.
FAQs
1) Is sodium bicarbonate considered off-patent in major markets?
Yes in practice, with any remaining protections usually product-specific rather than protecting the active ingredient broadly.
2) What dosage forms of sodium bicarbonate have the most regulatory and manufacturing scrutiny?
Injectables and tightly specified grades typically face the strictest CMC expectations.
3) Does sodium bicarbonate have meaningful FDA exclusivity periods?
For most products, exclusivity is limited; pricing and volume are more impacted by generic competition and contracting.
4) What is the biggest investor risk for sodium bicarbonate producers?
Batch release and regulatory compliance failures that can interrupt supply and trigger contract losses.
5) Can sodium bicarbonate deliver brand-like pricing power?
Usually not; substitutability and multi-source availability cap pricing, making cost and reliability the main determinants.
References
No sources were cited.
More… ↓
